People: Prometic Life Sciences Inc (PLI.TO)
23 Jul 2019
Dr.Gary J. Bridger is Director of the company. Dr.Gary Bridgerhas served as a member of the board of directors of X4 Pharmaceuticals, Inc. sinceOctober 2018. FromFebruary 2015toDecember 2017, Dr. Bridger served as a consultant to Xenon Pharmaceuticals Inc., a biopharmaceutical company, where he previously served as the Executive Vice President of Research and Development fromJanuary 2013toFebruary 2015. FromOctober 2013toOctober 2015, Dr. Bridger served as a Managing Director at Five Corners Capital Inc. FromJune 2010toJune 2012, Dr. Bridger served as a venture partner at Venture West Capital Management, a venture capital firm. FromNovember 2006toDecember 2007, Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. InJune 1996, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme inNovember 2006. Dr. Bridger has served on the board of directors of Aquinox Pharmaceuticals, Inc. since 2013. Dr. Bridger previously served on the board of directors of Alder BioPharmaceuticals, Inc., a biopharmaceutical company, from 2013 to 2016. Dr. Bridger serves on the scientific advisory board of Alectos Therapeutics Inc., a biopharmaceutical company. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|